Nanotechnology based drug delivery system

1826 Words8 Pages
Introduction: Mycobacterium tuberculosis (MTB) is found in about 30 to 35% of the world’s population which is mostly in latent phase while, the active phase of TB is fatally mortal and found in about 10% of the infected population. According to World Health Organization (WHO) reports of 2012, 8.6 million people were infected with this deadly communicable disease out of which 1.3 million of the population died from TB and about 26% of the global cases solely accounted were from India. TB is considered as a poor man’s disease and large population affected are found to be either in unhygienic conditions or it has been observed in population with poor lifestyle. The diagnostic measures has been ineffective up to some extent suggesting developing promising techniques with which the demographic condition can be improved. Mycobacterium Tuberculosis has been one of the causes in most preventable deaths as of today after cancer. It has also been noted that with the fall in immunity, the latent TB hosts show rise in Tubercular activity and in turn linked with Human Immuno-deficiency Virus (HIV) affected patients. The advent of developing improved Drug delivery systems (DDS) has brought a surge to researchers to kill the MTB which is prevalent in the macrophages inside granuloma cell found in lung tissue of the individual infected with MTB, thereby reducing the complications of the traditional therapies. Oral drug delivery is the one of the most favourable and convenient routes for drug administration for the motive of better patient compliance and due to its non-invasive nature. It is not only advantageous to patient but it eliminates the pain and discomfort as compared to injections. Oral route is preferred in case with drugs having high... ... middle of paper ... ... as the New Anti-Tubercular drugs takes long span of time to come for patient use. Meanwhile, Researchers try to minimise the side effects of existing drugs by trying Combination of drugs, reducing the dose, Shorten the therapy and modifying the release of the drugs which enables to reduce the frequency of the dosage form. Taking into consideration these advantages one can conclude that Nanotechnology based systems improve the treatment regimen in case of TB patients and could possibly shorten the treatment regimen giving compliance to the patients of TB. Another Challenge is commercial aspect of producing these Nanotechnology based systems. In scaling up techniques, Cost increases along with the regulatory status of the FDA requirements. Heavy investments are observed in Advanced Instrumentation in areas where market potential of the drug is of utmost priority.
Open Document